Evidence map›Paper›PMID 38014221›Full record

ArticlemedRxiv : the preprint server for health sciences2023

Spatial proteo-transcriptomic profiling reveals the molecular landscape of borderline ovarian tumors and their invasive progression.

Lisa Schweizer, Rahul Krishnan, Aasa Shimizu, Andreas Metousis, Hilary Kenny, Rachelle Mendoza, Thierry M Nordmann, Sarah Rauch, Lucy Kelliher, Janna Heide and 13 more

Open access · greenAbstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in medRxiv : the preprint server for health sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 7 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

23 authors at 3 institutions in 3 countries.

Lisa SchweizerProteomics and Signal Transduction, Max Planck Institute of Biochemistry, Martinsried, Germany.
Rahul KrishnanDepartment of Obstetrics and Gynecology/Section of Gynecologic Oncology, University of Chicago, Chicago, IL, USA.
Aasa ShimizuDepartment of Obstetrics and Gynecology/Section of Gynecologic Oncology, University of Chicago, Chicago, IL, USA.
Andreas MetousisProteomics and Signal Transduction, Max Planck Institute of Biochemistry, Martinsried, Germany.
Hilary KennyDepartment of Obstetrics and Gynecology/Section of Gynecologic Oncology, University of Chicago, Chicago, IL, USA.
Rachelle MendozaDepartment of Pathology, The University of Chicago, Chicago, IL, USA.
Thierry M NordmannProteomics and Signal Transduction, Max Planck Institute of Biochemistry, Martinsried, Germany.
Sarah RauchDepartment of Obstetrics and Gynecology/Section of Gynecologic Oncology, University of Chicago, Chicago, IL, USA.
Lucy KelliherDepartment of Obstetrics and Gynecology/Section of Gynecologic Oncology, University of Chicago, Chicago, IL, USA.
Janna HeideDepartment of Obstetrics and Gynecology/Section of Gynecologic Oncology, University of Chicago, Chicago, IL, USA.
Florian A RosenbergerProteomics and Signal Transduction, Max Planck Institute of Biochemistry, Martinsried, Germany.
Agnes BileczDepartment of Obstetrics and Gynecology/Section of Gynecologic Oncology, University of Chicago, Chicago, IL, USA.
Sanaa Nakad BorregoDepartment of Obstetrics and Gynecology/Section of Gynecologic Oncology, University of Chicago, Chicago, IL, USA.
Maximillian T StraussProteomics Program, Novo Nordisk Foundation Center for Protein Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
Marvin ThielertProteomics and Signal Transduction, Max Planck Institute of Biochemistry, Martinsried, Germany.
Edwin RodriguezProteomics and Signal Transduction, Max Planck Institute of Biochemistry, Martinsried, Germany.
Johannes B Müller-ReifProteomics and Signal Transduction, Max Planck Institute of Biochemistry, Martinsried, Germany.
Mengjie ChenMedicine/Section of Genetic Medicine, The University of Chicago, Chicago, IL, USA.
S Diane YamadaDepartment of Obstetrics and Gynecology/Section of Gynecologic Oncology, University of Chicago, Chicago, IL, USA.
Andreas MundProteomics Program, Novo Nordisk Foundation Center for Protein Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
Ricardo R LastraDepartment of Pathology, The University of Chicago, Chicago, IL, USA.
Matthias MannProteomics and Signal Transduction, Max Planck Institute of Biochemistry, Martinsried, Germany.
Ernst LengyelDepartment of Obstetrics and Gynecology/Section of Gynecologic Oncology, University of Chicago, Chicago, IL, USA.
University of Chicago · USMax Planck Institute of Biochemistry · DEUniversity of Copenhagen · DK

Funding

VIRAL ONCOLOGY CORE FACILITYP30CA014599 · NCI · UNIVERSITY OF CHICAGO · PI KUNLE ODUNSI · 1985 to 2026
$122.1M
Metabolic reprogramming of the tumor microenvironment and therapy resistanceR35CA264619 · NCI · UNIVERSITY OF CHICAGO · PI Ernst Lengyel · 2021 to 2026
$5.2M
NCI NIH HHS P30 CA014599NCI NIH HHS R35 CA264619
6 · The paper itself

Abstract

Serous borderline tumors (SBT) are epithelial neoplastic lesions of the ovaries that commonly have a good prognosis. In 10-15% of cases, however, SBT will recur as low-grade serous cancer (LGSC), which is deeply invasive and responds poorly to current standard chemotherapy

Identifiers

PMID38014221
PMCPMC10680885
OpenAlexW4388647601

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.